DE69231123T2 - Konjugaten von Zell-bindender Mittel und Derivaten von CC-1065 - Google Patents

Konjugaten von Zell-bindender Mittel und Derivaten von CC-1065

Info

Publication number
DE69231123T2
DE69231123T2 DE69231123T DE69231123T DE69231123T2 DE 69231123 T2 DE69231123 T2 DE 69231123T2 DE 69231123 T DE69231123 T DE 69231123T DE 69231123 T DE69231123 T DE 69231123T DE 69231123 T2 DE69231123 T2 DE 69231123T2
Authority
DE
Germany
Prior art keywords
conjugates
derivatives
cell
binding agents
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69231123T
Other languages
English (en)
Other versions
DE69231123D1 (de
Inventor
Ravi V J Chari
Viktor S Goldmakher
Walter A Blattler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunogen Inc
Original Assignee
Immunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunogen Inc filed Critical Immunogen Inc
Application granted granted Critical
Publication of DE69231123D1 publication Critical patent/DE69231123D1/de
Publication of DE69231123T2 publication Critical patent/DE69231123T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
DE69231123T 1992-03-25 1992-08-20 Konjugaten von Zell-bindender Mittel und Derivaten von CC-1065 Expired - Lifetime DE69231123T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US85717192A 1992-03-25 1992-03-25

Publications (2)

Publication Number Publication Date
DE69231123D1 DE69231123D1 (de) 2000-07-06
DE69231123T2 true DE69231123T2 (de) 2001-02-15

Family

ID=25325372

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69231123T Expired - Lifetime DE69231123T2 (de) 1992-03-25 1992-08-20 Konjugaten von Zell-bindender Mittel und Derivaten von CC-1065

Country Status (8)

Country Link
US (3) US5475092A (de)
EP (1) EP0563475B1 (de)
JP (1) JP3700091B2 (de)
CA (1) CA2076465C (de)
DE (1) DE69231123T2 (de)
DK (1) DK0563475T3 (de)
ES (1) ES2149768T3 (de)
HK (1) HK1014674A1 (de)

Families Citing this family (353)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851526A (en) * 1985-04-19 1998-12-22 Ludwig Institute For Cancer Research Methods of treating colon cancer utilizing tumor-specific antibodies
US5780446A (en) * 1996-07-09 1998-07-14 Baylor College Of Medicine Formulations of vesicant drugs and methods of use thereof
US6368598B1 (en) 1996-09-16 2002-04-09 Jcrt Radiation Oncology Support Services, Inc. Drug complex for treatment of metastatic prostate cancer
US20030176512A1 (en) * 1998-08-11 2003-09-18 Kirkpatrick D. Lynn Asymmetric disulfides and methods of using same
US6552060B1 (en) 1997-08-11 2003-04-22 Prolx Pharmaceuticals, Inc. Asymmetric disulfides and methods of using same
IL135616A0 (en) * 1997-10-14 2001-05-20 Scripps Research Inst Iso-cbi and iso-ci analogs of cc-1065 and the duocarmycins
CA2313231A1 (en) * 1997-12-08 1999-06-17 The Scripps Research Institute Synthesis of cc-1065/duocarmycin analogs
US20030003507A1 (en) * 1999-06-02 2003-01-02 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP1140198B1 (de) 1999-01-13 2007-10-31 Alchemia Oncology Pty Limited Verwendung von hyaluronan zur herstellung eines medikaments zur erhöhung der wirksamkeit von zytotoxischen arzneimitteln
JP4812167B2 (ja) * 1999-02-12 2011-11-09 モレキュラー インサイト ファーマスーティカルズ インコーポレイテッド 薬物輸送用マトリックス、ならびにその作成方法および使用方法
EP2266607A3 (de) 1999-10-01 2011-04-20 Immunogen, Inc. Immunokonjugate für Krebsbehandlung
AU765588C (en) 1999-11-24 2004-12-16 Immunogen, Inc. Cytotoxic agents comprising taxanes and their therapeutic use
ATE317711T1 (de) * 1999-12-03 2006-03-15 Yissum Res Dev Co Elektropolymerisierbare monomere und polymerbeschichtungen auf implantierbaren geräten
US20060013850A1 (en) * 1999-12-03 2006-01-19 Domb Abraham J Electropolymerizable monomers and polymeric coatings on implantable devices prepared therefrom
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
AU2001269885A1 (en) * 2000-06-14 2001-12-24 The Scripps Research Institute Distamycin a analogs
AUPQ879500A0 (en) * 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
US9066919B2 (en) 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
US7626026B2 (en) 2001-02-22 2009-12-01 University Of Bradford Pyrrolo-indole and pyrrolo-quinoline derivatives as prodrugs for tumour treatment
US7157458B2 (en) 2001-04-17 2007-01-02 Cryolife, Inc. Bifunctional energy-reversible acyl-compositions
US20110313230A1 (en) 2001-05-11 2011-12-22 Terrance Grant Johns Specific binding proteins and uses thereof
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
DK2163256T3 (en) 2001-05-11 2015-12-07 Ludwig Inst For Cancer Res Ltd Specific binding proteins and use thereof
NZ529788A (en) 2001-05-31 2003-12-19 Medarex Inc Cytotoxins, prodrugs, linkers and stabilizers useful therefor
US7514078B2 (en) 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
WO2002098897A2 (en) 2001-06-01 2002-12-12 Cornell Research Foundation, Inc. Modified antibodies to prostate-specific membrane antigen and uses thereof
WO2003018062A1 (en) * 2001-08-27 2003-03-06 Meditech Research Limited Improved therapeutic protocols
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
DE10147672A1 (de) * 2001-09-27 2003-04-10 Bayer Ag Substituierte 2,5-Diamidoindole und ihre Verwendung
AU2002366803A1 (en) 2001-12-19 2003-07-09 Millennium Pharmaceuticals, Inc. Human diacylglycerol acyltransferase 2 (dgat2) family members and uses therefor
US6756397B2 (en) * 2002-04-05 2004-06-29 Immunogen, Inc. Prodrugs of CC-1065 analogs
AU2002303430A1 (en) * 2002-04-23 2003-11-10 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20040249130A1 (en) * 2002-06-18 2004-12-09 Martin Stanton Aptamer-toxin molecules and methods for using same
JP2005533794A (ja) * 2002-06-18 2005-11-10 アーケミックス コーポレイション アプタマー−毒素分子およびこれを使用する方法
JP2006502110A (ja) * 2002-07-03 2006-01-19 イミュノジェン・インコーポレーテッド 非放出Ｍｕｃ１およびＭｕｃ１６に対する抗体、およびその使用
BR0313197A (pt) 2002-08-02 2005-08-09 Immunogen Inc Agentes citotóxicos contendo potentes taxanos e seu uso terapêutico
US7390898B2 (en) * 2002-08-02 2008-06-24 Immunogen Inc. Cytotoxic agents containing novel potent taxanes and their therapeutic use
AU2003287160A1 (en) * 2002-10-15 2004-05-04 Rigel Pharmaceuticals, Inc. Substituted indoles and their use as hcv inhibitors
US8853376B2 (en) 2002-11-21 2014-10-07 Archemix Llc Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
CA2930485C (en) 2003-05-14 2018-04-10 Immunogen, Inc. Maytansinoid-antibody conjugate compositions
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
EP1713900A4 (de) * 2004-01-27 2009-06-17 Compugen Ltd Verfahren und systeme zur kommentierung biomolekularer sequenzen
WO2005071059A2 (en) * 2004-01-27 2005-08-04 Compugen Ltd. Methods of identifying putative gene products by interspecies sequence comparison and biomolecular sequences uncovered thereby
AU2005241009A1 (en) * 2004-04-21 2005-11-17 Mcmaster University Myosin light chain kinase inhibitors and their use
US7691962B2 (en) 2004-05-19 2010-04-06 Medarex, Inc. Chemical linkers and conjugates thereof
CA2564076C (en) * 2004-05-19 2014-02-18 Medarex, Inc. Chemical linkers and conjugates thereof
US7541330B2 (en) * 2004-06-15 2009-06-02 Kosan Biosciences Incorporated Conjugates with reduced adverse systemic effects
RU2007103298A (ru) * 2004-06-30 2008-08-10 Новартис АГ (CH) Композиции и способы доставки противоопухолевых агентов
CA2486285C (en) * 2004-08-30 2017-03-07 Viktor S. Goldmakher Immunoconjugates targeting syndecan-1 expressing cells and use thereof
US20110166319A1 (en) * 2005-02-11 2011-07-07 Immunogen, Inc. Process for preparing purified drug conjugates
AU2006213662B2 (en) 2005-02-11 2010-08-05 Immunogen, Inc. Process for preparing stable drug conjugates
EP2384767B1 (de) 2005-03-24 2016-03-09 Millennium Pharmaceuticals, Inc. OV064-bindende Antikörper und Verfahren zu deren Verwendung
US7714016B2 (en) 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates
CN103784960A (zh) * 2005-07-27 2014-05-14 阿尔卡米亚肿瘤学股份有限公司 使用乙酰透明质酸的治疗方案
NZ599176A (en) * 2005-08-03 2014-04-30 Immunogen Inc Immunoconjugate formulations
EP1928503B1 (de) * 2005-08-24 2012-10-03 ImmunoGen, Inc. Verfahren zur herstellung von maytansinoid-antikörper-konjugaten
EA013877B1 (ru) 2005-09-07 2010-08-30 Алкемиа Онколоджи Пти Лимитед Терапевтические композиции, содержащие гиалуроновую кислоту и терапевтические антитела, а также способы лечения
CA2623236A1 (en) * 2005-09-26 2007-04-05 Medarex, Inc. Human monoclonal antibodies to cd70
SI1940789T1 (sl) 2005-10-26 2012-03-30 Medarex Inc Postopki in spojine za pripravo cc analogov
CA2627190A1 (en) 2005-11-10 2007-05-24 Medarex, Inc. Duocarmycin derivatives as novel cytotoxic compounds and conjugates
US20070264687A1 (en) 2005-12-15 2007-11-15 Min-Yuan Chou Recombinant triplex scaffold-based polypeptides
US10183986B2 (en) 2005-12-15 2019-01-22 Industrial Technology Research Institute Trimeric collagen scaffold antibodies
EP1806365A1 (de) 2006-01-05 2007-07-11 Boehringer Ingelheim International GmbH Antikörper spezifisch für Fibroblasten-Aktivierungsprotein und Immunokonjugaten, die diese Antikörper enthalten
EP1813614B1 (de) 2006-01-25 2011-10-05 Sanofi Neue Tomaymycin Derivate enhaltende zytotoxische Mittel
MX2008009956A (es) * 2006-02-02 2008-12-12 Syntarga Bv Analogos de cc-1065 solubles en agua y sus conjugados.
EP1832577A1 (de) * 2006-03-07 2007-09-12 Sanofi-Aventis Verbesserte Pro-Pharmaka von CC-1065-Analoga
EP1864682A1 (de) 2006-06-09 2007-12-12 Sanofi-Aventis Leptomycinderivate
WO2008010101A2 (en) * 2006-07-18 2008-01-24 Sanofi-Aventis Antagonist antibody against epha2 for the treatment of cancer
EP1914242A1 (de) * 2006-10-19 2008-04-23 Sanofi-Aventis Neue Antikörper gegen CD38 zur Behandlung von Krebs
JP5537946B2 (ja) 2006-11-22 2014-07-02 ブリストル−マイヤーズ スクイブ カンパニー Ｉｇｆ−ｉｒを含むチロシンキナーゼ受容体に対する改変タンパク質に基づく標的治療薬
MX2009006277A (es) * 2006-12-14 2009-07-24 Medarex Inc Anticuerpos humanos que se enlazan a cd70 y usos de los mismos.
TWI412367B (zh) 2006-12-28 2013-10-21 Medarex Llc 化學鏈接劑與可裂解基質以及其之綴合物
CN104013956B (zh) 2007-01-25 2018-12-18 达娜-法勃肿瘤研究所公司 抗egfr抗体在治疗egfr突变体介导的疾病中的用途
WO2008097497A2 (en) 2007-02-02 2008-08-14 Adnexus, A Bristol-Myers Squibb R & D Company Vegf pathway blockade
KR20090122439A (ko) * 2007-02-21 2009-11-30 메다렉스, 인코포레이티드 단일 아미노산을 갖는 화학적 링커 및 이의 접합체
MX2009009782A (es) 2007-03-15 2010-09-10 Ludwig Inst Cancer Res Metodo de tratamiento que utiliza anticuerpos egfr e inhibidores de src y formulaciones relacionadas.
CN101679974B (zh) 2007-03-27 2015-09-30 航道生物技术有限责任公司 包含抗体替代轻链序列的构建体和文库
JP2008297203A (ja) * 2007-05-29 2008-12-11 Chisso Corp 複合体
SI2019104T1 (sl) * 2007-07-19 2013-12-31 Sanofi Citotoksična sredstva, ki obsegajo nove tomaimicinske derivate, in njihova terapevtska uporaba
US9901567B2 (en) 2007-08-01 2018-02-27 Syntarga B.V. Substituted CC-1065 analogs and their conjugates
PE20120259A1 (es) 2007-08-09 2012-04-04 Boehringer Ingelheim Int Anticuerpos anti-cd37
EP2188311B1 (de) 2007-08-14 2016-10-05 Ludwig Institute for Cancer Research Ltd. Auf den egf-rezeptor zielender, monoklonaler antikörper 175 und derivate und anwendungen davon
MX338474B (es) * 2007-08-29 2016-04-18 Sanofi Aventis Anticuerpos anti - cxcr5 humanizados, derivados de los mismos y su uso.
JP5951929B2 (ja) 2007-10-03 2016-07-13 コーネル ユニヴァーシティー Ｐｓｍａ抗体を用いる増殖性障害の治療
EP2050764A1 (de) 2007-10-15 2009-04-22 sanofi-aventis Neues polyvalentes bispezifisches Antikörperformat und Verwendung
CA2710483C (en) * 2007-12-26 2018-05-08 Biotest Ag Methods and agents for improving targeting of cd138 expressing tumor cells
KR101654822B1 (ko) * 2007-12-26 2016-09-06 바이오테스트 아게 Ｃｄ138 표적성 면역접합체 및 이의 용도
CN101952315B (zh) * 2007-12-26 2015-04-01 生物测试股份公司 靶向cd138的试剂及其应用
AR069979A1 (es) * 2007-12-26 2010-03-03 Biotest Ag Metodo para disminuir los efectos secundarios citotoxicos y mejorar la eficacia de los inmunoconjugados
US20110052501A1 (en) * 2008-01-31 2011-03-03 Liat Dassa Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
KR20210131473A (ko) 2008-03-18 2021-11-02 제넨테크, 인크. 항-ｈｅｒ２ 항체-약물 접합체와 화학요법제의 병용물, 및 사용 방법
EP2862871A1 (de) 2008-04-14 2015-04-22 The General Hospital Corporation Auf plectin-1 gerichtete Wirkstoffe für den Nachweis und die Behandlung von duktalem Adenokarzinom des Pankreas
MY186725A (en) 2008-04-30 2021-08-13 Immunogen Inc Cross-linkers and their uses
US20100092495A1 (en) * 2008-04-30 2010-04-15 Immunogen Inc. Potent cell-binding agent drug conjugates
WO2009142773A2 (en) 2008-05-22 2009-11-26 Bristol-Myers Squibb Company Multivalent fibronectin based scaffold domain proteins
MX2011002478A (es) 2008-09-07 2011-04-05 Glyconex Inc Anticuerpo anti-glucoesfingolipido tipo i extendido, derivados del mismo y su uso.
EP3622968A1 (de) 2008-10-31 2020-03-18 The General Hospital Corporation Zusammensetzungen und verfahren zur abgabe einer substanz an ein biologisches target
NO2344478T3 (de) 2008-11-03 2018-02-24
JP5977522B2 (ja) 2009-02-05 2016-08-24 イミュノジェン・インコーポレーテッド 新規ベンゾジアゼピン誘導体
ES2712732T3 (es) 2009-02-17 2019-05-14 Cornell Res Foundation Inc Métodos y kits para el diagnóstico de cáncer y la predicción de valor terapéutico
US9238878B2 (en) 2009-02-17 2016-01-19 Redwood Bioscience, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
EP2424875B1 (de) 2009-04-29 2016-01-06 Bio-Rad Laboratories, Inc. Reinigung von immunkonjugaten
WO2010126551A1 (en) 2009-04-30 2010-11-04 Immunogen, Inc. Potent conjugates and hydrophilic linkers
WO2010126552A1 (en) * 2009-04-30 2010-11-04 Immunogen, Inc. Potent cell-binding agent drug conjugates
AU2010249003B2 (en) 2009-05-13 2015-08-20 Genzyme Corporation Anti-human CD52 immunoglobulins
EP2430047B1 (de) 2009-05-13 2018-03-28 i2 Pharmaceuticals, Inc. Neutralisierende moleküle gegen influenza-viren
PT2437790T (pt) 2009-06-03 2019-06-04 Immunogen Inc Métodos de conjugação
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
US20110076232A1 (en) 2009-09-29 2011-03-31 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
AR078470A1 (es) 2009-10-02 2011-11-09 Sanofi Aventis Anticuerpos que se unen especificamente al receptor epha2
JP5841072B2 (ja) 2010-02-10 2016-01-06 イミュノジェン・インコーポレーテッド Ｃｄ２０抗体およびその使用
SG10201501342UA (en) 2010-02-24 2015-04-29 Immunogen Inc Folate receptor 1 antibodies and immunoconjugates and uses thereof
CN102971012B (zh) 2010-03-12 2016-05-04 伊缪诺金公司 Cd37结合分子及其免疫缀合物
EP3222632A1 (de) 2010-03-26 2017-09-27 Memorial Sloan-Kettering Cancer Center Antikörper gegen muc16 und verfahren zur verwendung davon
WO2011133555A2 (en) 2010-04-20 2011-10-27 The Research Foundation Of State University Of New York Compositions and methods for inhibiting matrix metalloproteinase (mmp)-mediated cell migration
LT2560645T (lt) * 2010-04-21 2016-10-10 Syntarga B.V. Cc-1065 analogų ir bifunkcinių linkerių konjugatai
AU2011283694B2 (en) 2010-07-29 2017-04-13 Xencor, Inc. Antibodies with modified isoelectric points
WO2012019024A2 (en) 2010-08-04 2012-02-09 Immunogen, Inc. Her3-binding molecules and immunoconjugates thereof
US9228023B2 (en) 2010-10-01 2016-01-05 Oxford Biotherapeutics Ltd. Anti-ROR1 antibodies and methods of use for treatment of cancer
AU2011320314B2 (en) 2010-10-29 2015-08-06 Immunogen, Inc. Novel EGFR-binding molecules and immunoconjugates thereof
AU2011320318B9 (en) 2010-10-29 2015-11-19 Immunogen, Inc. Non-antagonistic EGFR-binding molecules and immunoconjugates thereof
WO2012075173A2 (en) 2010-12-01 2012-06-07 Board Of Regents The University Of Texas System Compositions and method for deimmunization of proteins
WO2012078868A1 (en) 2010-12-09 2012-06-14 Immunogen, Inc. Methods for the preparation of charged crosslinkers
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
BR112013017980A2 (pt) 2011-01-14 2017-06-27 Redwood Bioscience Inc polipeptídeos de imunoglobulina marcado com aldeído e método de uso dos mesmos
WO2012106368A2 (en) 2011-01-31 2012-08-09 The Regents Of The University Of California Methods for inhibiting prostate cancer
SG10201601046QA (en) 2011-02-15 2016-03-30 Immunogen Inc Cytotoxic benzodiazepine derivatives
JP2014510730A (ja) 2011-03-16 2014-05-01 サノフイ デュアルｖ領域抗体様タンパク質の使用
SG193997A1 (en) 2011-03-29 2013-11-29 Immunogen Inc Process for manufacturing conjugates of improved homogeneity
TR201902180T4 (tr) 2011-03-29 2019-03-21 Immunogen Inc Tek adimli bi̇r i̇şlem i̇le maytansi̇noi̇d anti̇kor konjugatlarinin hazirlanmasi
WO2012171020A1 (en) 2011-06-10 2012-12-13 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
MX350954B (es) 2011-06-21 2017-09-26 Immunogen Inc Derivados de maitansinoides novedosos con enlazador de peptido y conjugados de estos.
WO2013016714A1 (en) 2011-07-28 2013-01-31 Sea Lane Biotechnologies Sur-binding proteins against erbb3
WO2013022855A1 (en) 2011-08-05 2013-02-14 Xencor, Inc. Antibodies with modified isoelectric points and immunofiltering
PE20141151A1 (es) 2011-09-22 2014-09-25 Amgen Inc Proteinas de union al antigeno cd27l
SG10201602654SA (en) 2011-10-03 2016-05-30 Moderna Therapeutics Inc Modified nucleosides,nucleotides,and nucleic acids,and uses thereof
AU2012323287B2 (en) 2011-10-10 2018-02-01 Xencor, Inc. A method for purifying antibodies
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
KR20140105765A (ko) 2011-11-21 2014-09-02 이뮤노젠 아이엔씨 EGfr 항체 세포독성제 접합체에 의한 EGfr 치료에 내성을 나타내는 종양의 치료 방법
MX358680B (es) 2011-12-08 2018-08-31 Biotest Ag Usos de inmunoconjugados dirigidos a cd138.
CA3018046A1 (en) 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
CA2859744A1 (en) 2011-12-22 2013-06-27 Sea Lane Biotechnologies, Llc Surrogate binding proteins
WO2013109994A1 (en) 2012-01-20 2013-07-25 Sea Lane Biotechnologies, Llc Surrobody cojugates
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
AU2013243950A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides
WO2013151649A1 (en) 2012-04-04 2013-10-10 Sialix Inc Glycan-interacting compounds
JP2015516980A (ja) 2012-04-26 2015-06-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｄ３７抗体とベンダムスチンとの併用
JP2015517512A (ja) 2012-05-16 2015-06-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｄ３７抗体の更なる薬剤との併用
US8992915B2 (en) 2012-05-16 2015-03-31 Boehringer Ingelheim International Gmbh Combination of CD37 antibodies with ICE
AR091069A1 (es) 2012-05-18 2014-12-30 Amgen Inc Proteinas de union a antigeno dirigidas contra el receptor st2
US20150104468A1 (en) 2012-06-04 2015-04-16 Irm Llc Site-specific labeling methods and molecules produced thereby
WO2014055877A1 (en) 2012-10-04 2014-04-10 Immunogen, Inc. Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates
WO2014065860A1 (en) 2012-10-24 2014-05-01 The General Hospital Corporation Functionalized 1,2,4,5-tetrazine compounds for use in bioorthogonal coupling reactions
RS55987B1 (sr) 2012-11-20 2017-09-29 Sanofi Sa Anti-ceacam5 antitela i njihova primena
JP6133431B2 (ja) 2012-11-24 2017-05-24 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ．Ｈａｎｇｚｈｏｕ Ｄａｃ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． 親水性連結体及び薬物分子と細胞結合分子との共役反応における親水性連結体の使用
PT2922554T (pt) 2012-11-26 2022-06-28 Modernatx Inc Arn modificado nas porções terminais
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
CA2892863C (en) 2012-12-10 2022-03-15 Mersana Therapeutics, Inc. Polymeric scaffold based on phf for targeted drug delivery
EP2928503B1 (de) 2012-12-10 2019-02-20 Mersana Therapeutics, Inc. Konjugate von auristatinverbindungen
EP2931316B1 (de) 2012-12-12 2019-02-20 Mersana Therapeutics, Inc. Hydroxylpolymer-heilmittelproteinkonjugate
AU2013369339B2 (en) 2012-12-27 2018-11-15 Sanofi Anti-LAMP1 antibodies and antibody drug conjugates, and uses thereof
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
CA3211863A1 (en) 2013-01-14 2014-07-17 Xencor, Inc. Novel heterodimeric proteins
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
CA2897987A1 (en) 2013-01-15 2014-07-24 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
EP3434774A1 (de) 2013-01-17 2019-01-30 ModernaTX, Inc. Signal-sensor-polynukleotide zur veränderung zellulärer phänotypen
ES2728936T3 (es) 2013-01-25 2019-10-29 Amgen Inc Anticuerpos dirigidos contra CDH19 para melanoma
WO2014124258A2 (en) 2013-02-08 2014-08-14 Irm Llc Specific sites for modifying antibodies to make immunoconjugates
MX2015010146A (es) 2013-02-08 2016-05-31 Novartis Ag Sitios especificos para modificar anticuerpos para hacer inmunoconjugados.
US20160024181A1 (en) 2013-03-13 2016-01-28 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
CN105007950B (zh) 2013-03-15 2019-01-15 诺华股份有限公司 抗体药物缀合物
KR102561553B1 (ko) 2013-03-15 2023-07-31 젠코어 인코포레이티드 이형이량체 단백질
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
EP2970486B1 (de) 2013-03-15 2018-05-16 Xencor, Inc. Modulation von t-zellen mit bispezifischen antikörpern und fc-fusionen
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
EP2981822B1 (de) 2013-05-06 2020-09-02 Scholar Rock, Inc. Zusammensetzungen und verfahren zur modulation von wachstumsfaktoren
PT3004167T (pt) 2013-05-30 2018-11-13 Kiniksa Pharmaceuticals Ltd Proteínas de ligação ao antigénio do recetor da oncostatina m
HUE056760T2 (hu) 2013-07-11 2022-03-28 Modernatx Inc A CRISPR-hez kapcsolódó fehérjéket és a szintetikus SGRNS-ket kódoló szintetikus polinukleotidokat tartalmazó készítmények és felhasználási módjaik
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
AU2014315287A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Chimeric polynucleotides
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
US10323076B2 (en) 2013-10-03 2019-06-18 Modernatx, Inc. Polynucleotides encoding low density lipoprotein receptor
RU2696579C2 (ru) 2013-10-08 2019-08-05 Иммьюноджен, Инк. Схемы применения иммуноконъюгата анти-folr1
CA2926586C (en) 2013-10-11 2020-04-07 Mersana Therapeutics, Inc. Polymeric scaffold based on phf for targeted drug delivery
EP3055331B1 (de) 2013-10-11 2021-02-17 Oxford Bio Therapeutics Limited Konjugierte antikörper gegen ly75 zur behandlung von krebs
ES2754397T3 (es) 2013-10-11 2020-04-17 Asana Biosciences Llc Conjugados de proteína-polímero-fármaco
PL2948183T3 (pl) 2014-01-10 2017-03-31 Synthon Biopharmaceuticals B.V. ADC duokarmycyny do zastosowania w leczeniu raka endometrium
PT3092010T (pt) 2014-01-10 2018-09-28 Synthon Biopharmaceuticals Bv Método para purificação de conjugados anticorpo-fármaco ligados por cys
CA2935433C (en) 2014-01-10 2019-04-02 Synthon Biopharmaceuticals B.V. Duocarmycin anti-her2 antibody drug conjucates with activity against her2 expressing malignancies
US9943606B2 (en) 2014-01-15 2018-04-17 Rutgers, The State University Of New Jersey Dendritic polypeptide-based nanocarriers for the delivery of therapeutic agents
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
ES2960619T3 (es) 2014-02-28 2024-03-05 Hangzhou Dac Biotech Co Ltd Enlazadores cargados y sus usos para la conjugación
MX2016011627A (es) 2014-03-12 2016-11-29 Novartis Ag Sitios especificos para modificar anticuerpos con el fin de hacer inmunoconjugados.
TWI697500B (zh) 2014-03-14 2020-07-01 瑞士商諾華公司 針對ｌａｇ-３之抗體分子及其用途
HUE048734T2 (hu) 2014-03-28 2020-08-28 Xencor Inc CD38-hoz és CD3-hoz kötõdõ bispecifikus ellenanyagok
US20170204152A1 (en) 2014-07-16 2017-07-20 Moderna Therapeutics, Inc. Chimeric polynucleotides
WO2016014846A1 (en) 2014-07-23 2016-01-28 Moderna Therapeutics, Inc. Modified polynucleotides for the production of intrabodies
US20160060360A1 (en) 2014-07-24 2016-03-03 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
US10786578B2 (en) 2014-08-05 2020-09-29 Novartis Ag CKIT antibody drug conjugates
US10179775B2 (en) 2014-08-11 2019-01-15 The General Hospital Corporation Cyclooctenes for bioorthogonol reactions
WO2016024195A1 (en) 2014-08-12 2016-02-18 Novartis Ag Anti-cdh6 antibody drug conjugates
KR20240011258A (ko) 2014-09-02 2024-01-25 이뮤노젠 아이엔씨 항체 약물 컨쥬게이트 조성물의 제형화 방법
JP6606545B2 (ja) 2014-09-03 2019-11-13 イミュノジェン・インコーポレーテッド 細胞障害性ベンゾジアゼピン誘導体
WO2016036804A1 (en) 2014-09-03 2016-03-10 Immunogen, Inc. Cytotoxic benzodiazepine derivatives
CA2960824A1 (en) 2014-09-13 2016-03-17 Novartis Ag Combination therapies of alk inhibitors
ES2774448T3 (es) 2014-10-03 2020-07-21 Novartis Ag Terapias de combinación
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
CN114920840A (zh) 2014-10-14 2022-08-19 诺华股份有限公司 针对pd-l1的抗体分子及其用途
WO2016073708A2 (en) 2014-11-05 2016-05-12 Dana-Farber Cancer Institute, Inc. Folate-conjugated molecules for delivery of toxic small molecule inhibitors to cancer cells and methods of use
US9879087B2 (en) 2014-11-12 2018-01-30 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
CA2967595A1 (en) 2014-11-12 2016-05-19 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
CN108064244B (zh) 2014-11-14 2021-09-17 诺华股份有限公司 抗体药物缀合物
CA2966932A1 (en) 2014-11-19 2016-05-26 Immunogen, Inc. Process for preparing cell-binding agent-cytotoxic agent conjugates
JP6696982B2 (ja) 2014-11-26 2020-05-20 ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． Ｃｄ３および腫瘍抗原に結合するヘテロ二量体抗体
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
MA41019A (fr) 2014-11-26 2021-05-05 Xencor Inc Anticorps hétérodimériques se liant aux antigènes cd3 et cd38
WO2016090157A1 (en) 2014-12-04 2016-06-09 Celgene Corporation Biomolecule conjugates
US20170340733A1 (en) 2014-12-19 2017-11-30 Novartis Ag Combination therapies
WO2016105450A2 (en) 2014-12-22 2016-06-30 Xencor, Inc. Trispecific antibodies
US10227411B2 (en) 2015-03-05 2019-03-12 Xencor, Inc. Modulation of T cells with bispecific antibodies and FC fusions
CN107667120B (zh) 2015-03-17 2022-03-08 纪念斯隆-凯特林癌症中心 抗muc16抗体及其应用
WO2016149485A1 (en) 2015-03-17 2016-09-22 The Regents Of The University Of California Novel chemoimmunotherapy for epithelial cancer
CA2980462C (en) 2015-04-07 2023-08-01 The Curators Of The University Of Missouri Nanoparticle immunoconjugates
EP3310813A1 (de) 2015-06-17 2018-04-25 Novartis AG Antikörper-wirkstoff-konjugate
WO2016210241A1 (en) 2015-06-26 2016-12-29 Beth Israel Deaconess Medical Center, Inc. Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells
PT3313845T (pt) 2015-06-29 2020-11-19 Immunogen Inc Conjugados de anticorpos de engenharia de cisteína
CN113350518A (zh) 2015-07-12 2021-09-07 杭州多禧生物科技有限公司 与细胞结合分子的共轭偶联的桥连接体
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
DK3325483T3 (da) 2015-07-21 2020-01-20 Immunogen Inc Fremgangsmåder til fremstilling af cytotoksiske benzodiazepinderivater
EP3317301B1 (de) 2015-07-29 2021-04-07 Novartis AG Kombinationstherapien mit antikörpermolekülen gegen lag-3
EP3316902A1 (de) 2015-07-29 2018-05-09 Novartis AG Kombinationstherapien mit antikörpermolekülen gegen tim-3
WO2017025458A1 (en) 2015-08-07 2017-02-16 Gamamabs Pharma Antibodies, antibody drug conjugates and methods of use
RU2749865C2 (ru) 2015-09-17 2021-06-17 Иммьюноджен, Инк. Терапевтические комбинации, содержащие анти-folr1 иммуноконъюгаты
DK3350333T3 (da) 2015-09-17 2022-01-31 Modernatx Inc Polynukleotider, der indeholder en stabiliserende haleregion
AU2016332900C1 (en) 2015-09-29 2024-02-01 Amgen Inc. ASGR inhibitors
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
IL258768B2 (en) 2015-11-12 2023-11-01 Siamab Therapeutics Inc Compounds interacting with glycans and methods of use
FI3380525T3 (fi) 2015-11-25 2024-01-30 Immunogen Inc Lääkeformulaatioita ja niiden käyttömenetelmiä
JP7058219B2 (ja) 2015-12-07 2022-04-21 ゼンコア インコーポレイテッド Ｃｄ３及びｐｓｍａに結合するヘテロ二量体抗体
JP2019503349A (ja) 2015-12-17 2019-02-07 ノバルティス アーゲー Ｐｄ−１に対する抗体分子およびその使用
JP2019502695A (ja) 2015-12-17 2019-01-31 ノバルティス アーゲー ＰＤ−１に対する抗体分子とＣ−Ｍｅｔ阻害剤との組合せおよびその使用
TW201731532A (zh) 2016-02-05 2017-09-16 伊繆諾金公司 用於製備細胞結合劑-細胞毒性劑結合物之有效方法
JP2019515677A (ja) 2016-04-26 2019-06-13 アール．ピー．シェーラー テクノロジーズ エルエルシー 抗体複合体ならびにそれを作製および使用する方法
WO2017194568A1 (en) 2016-05-11 2017-11-16 Sanofi Treatment regimen using anti-muc1 maytansinoid immunoconjugate antibody for the treatment of tumors
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
EP4257613A3 (de) 2016-06-14 2023-12-13 Xencor, Inc. Bispezifische antikörper gegen checkpoint-inhibitor
US11617799B2 (en) 2016-06-27 2023-04-04 Tagworks Pharmaceuticals B.V. Cleavable tetrazine used in bio-orthogonal drug activation
RU2019102008A (ru) 2016-06-28 2020-07-28 Ксенкор, Инк. Гетеродимерные антитела, которые связывают рецептор соматостатина 2-го типа
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
PE20191033A1 (es) 2016-10-14 2019-08-05 Xencor Inc PROTEINAS DE FUSION FC HETERODIMERICAS IL 15/IL 15R(alfa)
JP2020510608A (ja) 2016-11-02 2020-04-09 デビオファーム インターナショナル， エス． アー． 抗ｃｄ３７イムノコンジュゲート療法を改善するための方法
EP3538080A4 (de) 2016-11-14 2020-07-08 Hangzhou Dac Biotech Co., Ltd. Konjugationslinker, zellbindende molekül-wirkstoffkonjugate mit den linkern, verfahren zur herstellung und verwendung solcher konjugate mit den linkern
US11401330B2 (en) 2016-11-17 2022-08-02 Seagen Inc. Glycan-interacting compounds and methods of use
CA3044391A1 (en) 2016-11-23 2018-05-31 Immunogen, Inc. Selective sulfonation of benzodiazepine derivatives
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
JOP20190187A1 (ar) 2017-02-03 2019-08-01 Novartis Ag مترافقات عقار جسم مضاد لـ ccr7
TWI781145B (zh) 2017-02-28 2022-10-21 美商伊繆諾金公司 具有自分解肽連接子之類美登素衍生物及其結合物
WO2018160909A1 (en) 2017-03-03 2018-09-07 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
CN110545850A (zh) 2017-03-10 2019-12-06 奎亚培格制药公司 可释放的缀合物
WO2018185618A1 (en) 2017-04-03 2018-10-11 Novartis Ag Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
US20180346488A1 (en) 2017-04-20 2018-12-06 Immunogen, Inc. Cytotoxic benzodiazepine derivatives and conjugates thereof
AU2018255244A1 (en) 2017-04-21 2019-10-31 Mellitus, Llc Methods and antibodies for diabetes-related applications
US20200179511A1 (en) 2017-04-28 2020-06-11 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US20200172628A1 (en) 2017-06-22 2020-06-04 Novartis Ag Antibody molecules to cd73 and uses thereof
JP7433910B2 (ja) 2017-06-22 2024-02-20 ノバルティス アーゲー Ｃｄ７３に対する抗体分子及びその使用
CA3066754A1 (en) 2017-06-22 2018-12-27 Mersana Therapeutics, Inc. Methods of producing drug-carrying polymer scaffolds and protein-polymer-drug conjugates
CN111050791A (zh) 2017-06-27 2020-04-21 诺华股份有限公司 用于抗tim-3抗体的给药方案及其用途
WO2019006472A1 (en) 2017-06-30 2019-01-03 Xencor, Inc. TARGETED HETETRODIMERIC FUSION PROTEINS CONTAINING IL-15 / IL-15RA AND ANTIGEN-BINDING DOMAINS
JP2020527572A (ja) 2017-07-20 2020-09-10 ノバルティス アーゲー 抗ｌａｇ−３抗体の投薬量レジメンおよびその使用
WO2019016772A2 (en) 2017-07-21 2019-01-24 Novartis Ag COMPOSITIONS AND METHODS FOR TREATING CANCER
CN111225688A (zh) 2017-08-22 2020-06-02 普渡研究基金会 靶向碳酸酐酶阳性癌症的基于fbsa的治疗和放射性成像缀合物
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
KR20200085828A (ko) 2017-11-08 2020-07-15 젠코어 인코포레이티드 신규의 항-pd-1 서열을 사용한 이중특이적 및 단일특이적 항체
JP2021503478A (ja) 2017-11-16 2021-02-12 ノバルティス アーゲー 組み合わせ治療
MX2020006322A (es) 2017-12-19 2020-09-18 Xencor Inc Proteinas de fusion il-2 fc modificadas.
WO2019129137A1 (zh) 2017-12-27 2019-07-04 信达生物制药(苏州)有限公司 抗lag-3抗体及其用途
US11793885B2 (en) 2017-12-28 2023-10-24 Immunogen, Inc. Substituted benzo[5,6][1,4]diazepino[1,2-a]indoles for the treatment of proliferative disorders
CA3096052A1 (en) 2018-04-04 2019-10-10 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
US20210147547A1 (en) 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
CA3097741A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
CA3097593A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
EP3787691A1 (de) 2018-05-04 2021-03-10 Tagworks Pharmaceuticals B.V. Tetrazine für hohe clickkonjugationsausbeute in vivo und hohe clickfreisetzungsausbeute
EP3788032B1 (de) 2018-05-04 2024-01-24 Tagworks Pharmaceuticals B.V. Verbindungen mit einem linker zur erhöhung der transcyclooctenstabilität
EA202092967A1 (ru) 2018-05-30 2021-04-09 Дебиофарм Интернэшнл, С.А. Схемы приема иммуноконъюгата антитела против cd37
WO2019232244A2 (en) 2018-05-31 2019-12-05 Novartis Ag Antibody molecules to cd73 and uses thereof
EP3810269A2 (de) 2018-06-19 2021-04-28 Atarga, LLC Antikörpermoleküle zur ergänzung der komponente 5 und deren verwendungen
MA53094A (fr) 2018-07-02 2021-05-12 Amgen Inc Protéine de liaison à l'antigène anti-steap1
WO2020021465A1 (en) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) S.R.L. Method of treatment of neuroendocrine tumors
EP3849660A1 (de) 2018-09-12 2021-07-21 QuiaPEG Pharmaceuticals AB Lösbare glp-1-konjugate
AU2019355971A1 (en) 2018-10-03 2021-05-06 Xencor, Inc. IL-12 heterodimeric Fc-fusion proteins
CA3117050A1 (en) 2018-10-29 2020-05-07 Mersana Therapeutics, Inc. Cysteine engineered antibody-drug conjugates with peptide-containing linkers
US20230053449A1 (en) 2018-10-31 2023-02-23 Novartis Ag Dc-sign antibody drug conjugates
CN113194952A (zh) 2018-12-20 2021-07-30 诺华股份有限公司 Hdm2-p53相互作用抑制剂和bcl2抑制剂的组合及其治疗癌症的用途
SG11202106629PA (en) 2018-12-21 2021-07-29 Novartis Ag Antibodies to pmel17 and conjugates thereof
EP3693023A1 (de) 2019-02-11 2020-08-12 Sanofi Verwendung von anti-ceacam5-immunkonjugaten zur behandlung von lungenkrebs
SG11202107843WA (en) 2019-02-07 2021-08-30 Sanofi Sa Use of anti-ceacam5 immunoconjugates for treating lung cancer
US10871640B2 (en) 2019-02-15 2020-12-22 Perkinelmer Cellular Technologies Germany Gmbh Methods and systems for automated imaging of three-dimensional objects
MX2021010390A (es) 2019-03-01 2021-11-17 Xencor Inc Anticuerpos heterodimericos que se unen a enpp3 y cd3.
WO2020191342A1 (en) 2019-03-20 2020-09-24 The Regents Of The University Of California Claudin-6 antibodies and drug conjugates
CA3135430A1 (en) 2019-03-29 2020-10-08 Atarga, Llc Anti fgf23 antibody
EP3947395A1 (de) 2019-03-29 2022-02-09 ImmunoGen, Inc. Zytotoxische bis-benzodiazepinderivate und konjugate davon mit zellbindenden mitteln zur hemmung von abnormalem zellwachstum oder zur behandlung von proliferativen krankheiten
DK3958977T3 (en) 2019-04-26 2023-12-11 Immunogen Inc Camptothecinderivater
WO2020247054A1 (en) 2019-06-05 2020-12-10 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
WO2020256546A1 (en) 2019-06-17 2020-12-24 Tagworks Pharmaceuticals B.V. Compounds for fast and efficient click release
IL289094A (en) 2019-06-17 2022-02-01 Tagworks Pharmaceuticals B V Tetrazines for increasing the speed and yield of the "click release" reaction
CA3158298A1 (en) 2019-10-21 2021-04-29 Novartis Ag Combination therapies with venetoclax and tim-3 inhibitors
MX2022004769A (es) 2019-10-21 2022-05-16 Novartis Ag Inhibidores de tim-3 y sus usos.
EP4077389A1 (de) 2019-12-20 2022-10-26 Novartis AG Kombination des anti-tim-3-antikörpers mbg453 und des anti-tgf-beta-antikörpers nis793 mit oder ohne decitabin oder dem anti-pd-1-antikörper spartalizumab zur behandlung von myelofibrose und des myelodysplastischen syndroms
BR112022013255A2 (pt) 2020-01-09 2022-09-06 Mersana Therapeutics Inc Conjugados anticorpo-fármaco específicos de sítio com ligantes contendo peptídeo
US20230058489A1 (en) 2020-01-17 2023-02-23 Novartis Ag Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
CN115551552A (zh) 2020-02-25 2022-12-30 祐方有限公司 喜树碱衍生物及其缀合物
IL297222A (en) 2020-04-24 2022-12-01 Sanofi Sa Antitumor combinations containing conjugates of antibodies to ceacam5 and cetuximab
BR112022020592A2 (pt) 2020-04-24 2022-11-29 Sanofi Sa Combinações antitumor contendo conjugados de anticorpo anti-ceacam5, trifluridina e tipiracila
WO2021214221A1 (en) 2020-04-24 2021-10-28 Sanofi Antitumor combinations containing anti-ceacam5 antibody conjugates and folfiri
IL297311A (en) 2020-04-24 2022-12-01 Sanofi Sa Antitumor combinations containing conjugates of antibodies to ceacam5 and folfox
US20230181756A1 (en) 2020-04-30 2023-06-15 Novartis Ag Ccr7 antibody drug conjugates for treating cancer
EP3909601A1 (de) 2020-05-11 2021-11-17 LeukoCom GmbH Neuer antikörper, der spezifisch an menschliches ceacam1/3/5 bindet, und dessen verwendung
US11919956B2 (en) 2020-05-14 2024-03-05 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
WO2022010797A2 (en) 2020-07-07 2022-01-13 Bionecure Therapeutics, Inc. Novel maytansinoids as adc payloads and their use for the treatment of cancer
CN111777536B (zh) * 2020-07-14 2022-03-01 常州大学 一种制备不对称二硫醚的方法
WO2022026592A2 (en) 2020-07-28 2022-02-03 Celltas Bio, Inc. Antibody molecules to coronavirus and uses thereof
US20230321285A1 (en) 2020-08-31 2023-10-12 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
EP4204020A1 (de) 2020-08-31 2023-07-05 Advanced Accelerator Applications International S.A. Verfahren zur behandlung von psma-exprimierenden krebsarten
CN116615252A (zh) 2020-11-24 2023-08-18 诺华股份有限公司 抗cd48抗体、抗体药物缀合物及其用途
WO2022162569A1 (en) 2021-01-29 2022-08-04 Novartis Ag Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
US20220378929A1 (en) 2021-02-25 2022-12-01 MediBoston Limted Anti-her2 antibody-drug conjugates and uses thereof
CA3212665A1 (en) 2021-03-09 2022-09-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cldn6
US11859012B2 (en) 2021-03-10 2024-01-02 Xencor, Inc. Heterodimeric antibodies that bind CD3 and GPC3
WO2022195551A1 (en) 2021-03-18 2022-09-22 Novartis Ag Biomarkers for cancer and methods of use thereof
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
BR112023021475A2 (pt) 2021-04-16 2023-12-19 Novartis Ag Conjugados anticorpo-fármaco e métodos para produzir os mesmos
CA3230774A1 (en) 2021-09-06 2023-03-09 Veraxa Biotech Gmbh Novel aminoacyl-trna synthetase variants for genetic code expansion in eukaryotes
TW202333797A (zh) 2021-11-05 2023-09-01 法商賽諾菲公司 含有抗ceacam5抗體-藥物接合物及抗vegfr-2抗體之抗腫瘤組合
EP4186529A1 (de) 2021-11-25 2023-05-31 Veraxa Biotech GmbH Verbesserte antikörper-nutzlast-konjugate (aps), hergestellt durch ortsspezifische konjugation mittels genetischer codeerweiterung
WO2023094525A1 (en) 2021-11-25 2023-06-01 Veraxa Biotech Gmbh Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion
WO2023099683A1 (en) 2021-12-02 2023-06-08 Sanofi Cea assay for patient selection in cancer therapy
TW202340241A (zh) 2021-12-02 2023-10-16 法商賽諾菲公司 Ｃｅａｃａｍ５ ａｄｃ－抗ｐｄ１／ｐｄ－ｌ１組合療法
WO2023104941A1 (en) 2021-12-08 2023-06-15 European Molecular Biology Laboratory Hydrophilic tetrazine-functionalized payloads for preparation of targeting conjugates
WO2023150778A1 (en) 2022-02-07 2023-08-10 Visterra, Inc. Anti-idiotype antibody molecules and uses thereof
EP4314031B1 (de) 2022-02-15 2024-03-13 Tagworks Pharmaceuticals B.V. Maskiertes il12-protein
WO2024013724A1 (en) 2022-07-15 2024-01-18 Pheon Therapeutics Ltd Antibody-drug conjugates
US20240108744A1 (en) 2022-07-27 2024-04-04 Mediboston Limited Auristatin derivatives and conjugates thereof
WO2024030976A2 (en) 2022-08-03 2024-02-08 Voyager Therapeutics, Inc. Compositions and methods for crossing the blood brain barrier

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4169888A (en) * 1977-10-17 1979-10-02 The Upjohn Company Composition of matter and process
US4301248A (en) * 1979-12-21 1981-11-17 Bristol-Myers Company Fermentation process for making rachelmycin
CA1238907A (en) * 1984-02-21 1988-07-05 Robert C. Kelly 1,2,8,8a-tetrahydrocyclopropa¬c|pyrrolo(3,2-e)- indol-4(5h)-ones and related compounds
US4912227A (en) * 1984-02-21 1990-03-27 The Upjohn Company 1,2,8,8A-tetrahydrocyclopropa(c)pyrrolo(3,2-e)-indol-4-(5H)-ones and related compounds
IN165717B (de) * 1986-08-07 1989-12-23 Battelle Memorial Institute
MX9203200A (es) * 1986-12-19 1992-09-01 Upjohn Co Analogos de cc. 1065 novedosos.
EP0329184A3 (de) * 1988-02-19 1990-05-23 Neorx Corporation Antimere und antimere Konjugation
US5135736A (en) * 1988-08-15 1992-08-04 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
MX9203460A (es) * 1988-09-12 1992-09-01 Upjohn Co Nuevos analogos cc-1065 que tienen dos subunidades cpi.
KR0137959B1 (ko) * 1988-09-12 1998-05-15 로버트 에이. 아미테이지 2개의 cpi 소단위를 갖는 신규한 cc-1065 유사화합물
US5045451A (en) * 1988-10-26 1991-09-03 Board Of Regents Methods for screening antibodies for use as immunotoxins
CA2007431A1 (en) * 1989-01-10 1990-07-10 Larry W. Mclauglin Labeling of nucleic acids with fluorescent markers
KR100208957B1 (ko) * 1990-04-25 1999-07-15 로렌스 티. 마이젠헬더 신규한 cc-1065 유사체

Also Published As

Publication number Publication date
US5585499A (en) 1996-12-17
DK0563475T3 (da) 2000-09-18
US5846545A (en) 1998-12-08
ES2149768T3 (es) 2000-11-16
EP0563475B1 (de) 2000-05-31
DE69231123D1 (de) 2000-07-06
US5475092A (en) 1995-12-12
CA2076465A1 (en) 1993-09-26
HK1014674A1 (en) 1999-09-30
EP0563475A1 (de) 1993-10-06
JPH0656697A (ja) 1994-03-01
JP3700091B2 (ja) 2005-09-28
CA2076465C (en) 2002-11-26

Similar Documents

Publication Publication Date Title
DE69231123T2 (de) Konjugaten von Zell-bindender Mittel und Derivaten von CC-1065
DE69333929D1 (de) Konjugate von alginat und bioaktiven mitteln
DE69221059T2 (de) Indolderivate und antiulcerose Zubereitungen
DE68927417T2 (de) Oligoribonukleotid-Derivate und ihre Anwendung als antivirale Mittel
BR1100824A (pt) Composto e composição farmacêutica
DE69331967D1 (de) Gefässstent und zugehörige einführungsvorrichtung
EE9800459A (et) Spiro-piperidiini derivaadid ja nende kasutamine terapeutiliste toimeainetena
DE69419601D1 (de) Aminderivate und sie enthaltende dermatologische zubereitungen
DE10075003I1 (de) Neue antiparasitische Mittel derivate von Milbemycin und Avermectin
DE69509574T2 (de) Silikonvesikeln und Einschlussprodukte
DE69228373D1 (de) Kosmetikum und emulsion
GB9515775D0 (en) Piperidine derivatives and their use as therapeutic agents
DE69417897D1 (de) 2-hydroxypropandiaminderivate und diese enthaltende detergenzzubereitung
DE69223984D1 (de) Zusammensetzungen von difluormethan und tetrafluorethan
DE69304340D1 (de) Kosmetische mittel
NO944838D0 (no) Arabinogalaktanderivater og anvendelser derav
DE59708905D1 (de) Injektionsformulierungen von avermectinen und milbemycinen
DE69726007D1 (de) Prodrogs und analoga von camptothecin und deren verwendung als arzneimittel
DE68926733T2 (de) Piperidin-Derivate und diese enthaltende Hypotensiva
FI943100A (fi) Ansamysiinijohdannaisia antionkogeenisina ja syövänvastaisina aineina
DE69326588T2 (de) Carbapenemderivate als antibiotika und deren zwischenprodukte
DE69329933T2 (de) 17-beta-carboxanilid derivate von 4-aza-5-alpha-androstan-3-one als 5-alpha-reduktase-hemmende arzneimittel
DE69425210D1 (de) Cumarin derivate und deren anwendung
ATE100441T1 (de) Substituierte glutaramidsaeuren und derivate.
FI961977A0 (fi) N-substituoidut atsabisykloalkaanijohdannaiset, niiden valmistus ja käyttö

Legal Events

Date Code Title Description
8364 No opposition during term of opposition